Sign inJoin waitlistJoin the waitlist

JT

Joseph Treat

Physician · Lewis Katz School of Medicine at Temple University

Credentials: · ·

History

Lewis Katz School of Medicine at Temple University
2021–Present

Medical Oncology
1982–1984
Internal Medicine
1979–1982
Temple University School of Medicine
1975–1979

Research

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced…
Journal of Clinical Oncology · 2016 · 341 citations
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
Journal of Clinical Oncology · 2009 · 318 citations
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant…
Human Gene Therapy · 1998 · 276 citations

CO
Coleman Obasaju
14 papers
PW
Paul Woolley
11 papers
MS
Mark Socinski
8 papers
LK
Larry Kaiser
7 papers
Martin Edelman
7 papers
Hossein Borghaei
6 papers
Ruqin Chen
6 papers
CB
Chandra Belani
5 papers
Chao Huang
5 papers
Nicholas Bodor
5 papers
Andrew Greenspan
4 papers · 4 as a fellow
Corey Langer
4 papers

Grants

Immuno/Immuno-Gene Therapies for Thoracic Malignancies
National Cancer Institute · P01
Project lead · $450.8K · University of Pennsylvania
1997–2000
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $23.6K · University of Pennsylvania
1997–1998

Clinical trials

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Study chair · Withdrawn · Phase 3
Fox Chase Cancer Center
2001
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Study chair · Completed · Phase 3
SWOG Cancer Research Network
1999–2012
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Site PI · Recruiting · Phase 2
Lantern Pharma Inc.
2023–2027